Supplemental Table 1
Comparison of factors associated with not meeting the 1-year hormone therapy benchmark.

Patient characteristic (n=241)[a]	> 1 year (n = 9), n (%)	≤ 1 year (n = 232), n (%)	p-value
Age in years, mean (SD)	50 (9)	61 (12)	**.005**[d]
Race/Ethnicity			.078[c]
White	5 (56)	165 (72)	
Chinese origin	0 (0)	29 (13)	
Black/African-American	3 (33)	21 (9)	
Others	1 (11)	15 (7)	
Language			1.000[c]
English	8 (89)	197 (85)	
All others	1 (11)	35 (15)	
Census tract median household income, median (25th, 75th percentiles), $	53,517 (39,464-71,275)	74,357 (60,077-94,229)	.1008[e]
Insurance			1.000[c]
Private	4 (44)	98 (43)	
Any subsidized[b]	5 (56)	129 (57)	
Married/Partnered	5 (56)	94 (41)	.493[c]
Tumor stage			.058[c]
I	4 (44)	148 (64)	
II	2 (22)	65 (28)	
III	3 (33)	19 (8)	
Had multiple biopsies	2 (25)	31 (14)	.314[c]
Had family history of breast cancer	2 (25)	105 (46)	.298[c]
Had prior history of breast cancer treatment	1 (11)	18 (8)	.529[c]
Had comorbidity (Charlson score 1-8)	1 (11)	82 (35)	.169[c]

Bold denotes P < .05.

Abbreviation: SD = standard deviation.

[a]Patients with stage I to III estrogen receptor- and/or progesterone receptor-positive breast cancer who received hormone therapy.

[b]"Any subsidized" includes any Medicare, MassHealth (MA Medicaid), and/or any exchange product.

[c]Fisher exact test.

[d]t test.

[e]Mann-Whitney test.